Company Profile

DR. REDDYS LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE3256.50-20.35 (-0.62 % )
PREV CLOSE (Rs.) 3276.85
OPEN PRICE (Rs.) 3285.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 16014
TODAY'S LOW / HIGH (Rs.)3245.00 3363.00
52 WK LOW / HIGH (Rs.)2352 3363
NSE3255.30 -22.85 (-0.7 % )
PREV CLOSE(Rs.) 3278.15
OPEN PRICE (Rs.) 3289.30
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 3255.30 (431 )
VOLUME 924466
TODAY'S LOW / HIGH(Rs.) 3240.05 3364.95
52 WK LOW / HIGH (Rs.)2351.2 3364.95

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.61
TTM EPS (Rs.) 158.74
P/E Ratio 20.51
Book Value (Rs.) 884.09
Face Value (Rs.) 5
MCap (Rs. in Mn) 541110.29
Price/Earning (TTM) 15.74
Price/Sales (TTM) 5.02
Price/Book (MRQ) 3.68
PAT Margin (%) 12.02
ROCE (%) 12.49
Incorporation Year : 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Website : www.drreddys.com

Registrar's Details : Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York
NEWS More
19Feb02-19-2020$Dr. Reddys Laboratories informs about loss of share certificate Dr. Reddys Laboratories info

Pursuant to the Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Dr. Reddys Laboratories has informed that the share certificates are reported to have been lost by the shareholder Shashank Parvate (Folio Number-S01671) of the Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to the Regulation 39(3) of the SEBI (Listing Obligatio..
17Feb02-17-2020$USFDA completes audit at Dr. Reddy's Lab’s Formulations Srikakulam Plant USFDA completes audit at Dr.

US Food and Drug Administration (USFDA) has completed audit at Dr. Reddy's Laboratories’ Formulations Srikakulum Plant (SEZ) Unit I, Andhra Pradesh. The audit completed on February 14, 2020 with zero observation.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

US Food and Drug Administration (USFDA) has completed audit at..
17Feb02-17-2020$USFDA seeks voluntary action at Dr. Reddy's Andhra Pradesh facility USFDA seeks voluntary action

The US Food and Drug Administration (USFDA) has asked Dr. Reddy's Laboratories to initiate voluntary action at its Duvvada facility in Andhra Pradesh. The company has been notified by the USFDA that the inspection classification of the Formulations Manufacturing Plant at Duvvada, Visakhapatnam is determined as Voluntary Action Initiated (VAI).

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

The US Food and Drug Administration (USFDA) has asked Dr. Reddy..
17Feb02-17-2020$Bharti Airtel, Granules India and Dr. Reddy's to see some action today Bharti Airtel, Granules Indi

Bharti Airtel and Nokia, a global telecommunications equipment and service provider, have partnered to offer private LTE based Industry 4.0 solution to enterprises. The partnership will address the emerging requirements of enterprises across banking, financial services and insurance (BFSI), information technology enabled services (ITES), media and services, manufacturing and distribution with technologies such as cloud, IoT, artificial intelligence and machine learning, and edge computing concepts.

USFDA has completed inspection at Granules India's facility in Gagillapur located in Hyderabad, Telangana, India on February 14, 2020 with two observations. The company will respond to these observations within the stipulated time.

The audit of Dr. Reddy's Laboratories’ Formulations Srikakulum Plant (SEZ) Unit I, Andhra Pradesh by the USFDA, has been completed with zero observation.

Poddar Housing and Development has launched Phase I of its project known as ‘Poddar RIVIERA’ under PMAY scheme (Pradhan Mantri Awas Yojna) at kalyan. The Phase I of the said project is having 720 units with a built-up area of approximately 0.53 million sq. ft.

In line with its vision to strengthen international connectivity, InterGlobe Aviation (Indigo) has launched its new Delhi-Dammam flight effective March 10, 2020. Dammam was IndiGo's 24th international destination and 3rd in the Kingdom of Saudi Arabia after Jeddah and Riyadh. With this new addition, the airline will now operate a total of 05 daily direct flights connecting Dammam with Mumbai, Hyderabad, Kozhikode, Trivandrum and Delhi.

RITES has emerged as a successful bidder for supply of Locomotives, Coaches and DEMUs (Diesel electric Multiple Units) to a Cape Gauge country. RITES has submitted the price bid for the contract amount of around Rs 680 crore and discussion on contract documents are expected to conclude soon.

Ashoka Buildcon has received a Letter of Award (LOA) from National Highways Authority of India (NHAI) for the Project viz. Four Laning of Tumkur-Shivamogga section from Km 119+790 (Design Km 121+900) to Km 166+100 (Design Km170+415), Banwara to Bettadahalli section of NH-206 in the State of Karnataka, on Hybrid Annuity Mode under Bharatmala Priyojana (Package - III). The accepted Bid Project Cost is Rs 1,035.50 crore.

Bharti Airtel and Nokia, a global telecommunications equipment..
17Feb02-17-2020$Dr. Reddys inches up as USFDA completes audit at Formulations Srikakulum Plant Unit I Dr. Reddys inches up as USFD

Dr. Reddys Laboratories is currently trading at Rs. 3321.00, up by 13.50 points or 0.41% from its previous closing of Rs. 3307.50 on the BSE.

The scrip opened at Rs. 3312.00 and has touched a high and low of Rs. 3341.45 and Rs. 3304.05 respectively. So far 4752 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3,341.45 on 17-Feb-2020 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.

Last one week high and low of the scrip stood at Rs. 3,341.45 and Rs. 3115.00 respectively. The current market cap of the company is Rs. 55252.57 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.

US Food and Drug Administration (USFDA) has completed audit at Dr. Reddy's Laboratories’ Formulations Srikakulum Plant (SEZ) Unit I, Andhra Pradesh. The audit completed on February 14, 2020 with zero observation.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 3321.00, up..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit521712773
Gross Profit 6175 17007
Operating Profit 825025381
Net Sales 30440106255
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 7322.90 (2.05%)
M.Cap ( in Cr)
16865.09
Ajanta Pharma (BSE)
 1446.05 (10.03%)
M.Cap ( in Cr)
12618.42
Ipca Laboratories (BSE)
 1456.15 (3.43%)
M.Cap ( in Cr)
18398.76
Solara Active Pharma (BSE)
 680.25 (6.01%)
M.Cap ( in Cr)
1772.41
Alkem Laboratories (BSE)
 2657.75 (1.39%)
M.Cap ( in Cr)
31777.39
Shareholding Pattern More
MUTUAL FUNDS/UTI 9.29 %
FI/BANKS/INSURANCE 5.71 %
PROMOTERS 26.76 %
NON-INSTITUTION 13.8 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes